Monster Beverage Corporation (MNST)
NASDAQ: MNST · Real-Time Price · USD
64.69
+3.89 (6.40%)
At close: Aug 8, 2025, 4:00 PM
65.05
+0.36 (0.56%)
After-hours: Aug 8, 2025, 7:57 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $64.79, which forecasts a 0.15% increase in the stock price over the next year. The lowest target is $50 and the highest is $74.
Price Target: $64.79 (+0.15%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 6 | 6 | 6 | 6 | 7 | 5 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 17 | 16 | 16 | 17 | 17 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $70 → $74 | Strong Buy | Maintains | $70 → $74 | +14.39% | Aug 8, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $64 → $68 | Buy | Maintains | $64 → $68 | +5.12% | Aug 8, 2025 |
| UBS | UBS | Hold Maintains $64 → $67 | Hold | Maintains | $64 → $67 | +3.57% | Aug 8, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $73 | Buy | Maintains | $70 → $73 | +12.85% | Aug 8, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $66 → $72 | Strong Buy | Maintains | $66 → $72 | +11.30% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
8.10B
from 7.49B
Increased by 8.16%
Revenue Next Year
8.76B
from 8.10B
Increased by 8.03%
EPS This Year
1.89
from 1.49
Increased by 26.75%
EPS Next Year
2.11
from 1.89
Increased by 11.72%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.5B | 9.3B | 10.2B | ||
| Avg | 8.1B | 8.8B | 9.4B | ||
| Low | 7.6B | 7.9B | 8.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.6% | 15.2% | 16.1% | ||
| Avg | 8.2% | 8.0% | 7.1% | ||
| Low | 1.2% | -2.6% | -6.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.01 | 2.29 | 2.60 | ||
| Avg | 1.89 | 2.11 | 2.32 | ||
| Low | 1.74 | 1.83 | 1.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.9% | 21.2% | 23.4% | ||
| Avg | 26.7% | 11.7% | 9.9% | ||
| Low | 17.1% | -3.0% | -9.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.